Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Incyte Corp (NASDAQ:INCY)

84.41
Delayed Data
As of 4:00pm ET
 -0.12 / -0.14%
Today’s Change
55.00
Today|||52-Week Range
133.62
-22.17%
Year-to-Date
Investors Eager for Gilead to Make Big Moves
May 26 / TheStreet.com - Paid Partner Content
Gilead (GILD) Shares Spike After Exec. Board Appointment
May 25 / TheStreet.com - Paid Partner Content

Today’s Trading

Previous close84.53
Today’s open84.99
Day’s range83.84 - 86.20
Volume1,253,648
Average volume (3 months)1,944,822
Market cap$15.9B
Dividend yield--
Data as of 4:00pm ET, 05/31/2016

Growth & Valuation

Earnings growth (last year)--
Earnings growth (this year)+145.45%
Earnings growth (next 5 years)+56.00%
Revenue growth (last year)+47.36%
P/E ratio331.9
Price/Sales26.95
Price/Book92.18

Competitors

 Today’s
change
Today’s
% change
BMRNBiomarin Pharmaceuti...+0.56+0.63%
PRGOPerrigo Company PLC-0.77-0.80%
MDVNMedivation Inc-0.17-0.28%
MYLMylan NV+0.28+0.65%
Data as of 4:04pm ET, 05/31/2016

Financials

Next reporting dateJuly 28, 2016
EPS forecast (this quarter)-$0.02
Annual revenue (last year)$753.8M
Annual profit (last year)$6.5M
Net profit margin0.87%

Profile

Sector
Health Technology
Industry
Biotechnology
Chairman, President &
Chief Executive Officer
Hervé Hoppenot
Chief Financial Officer &
Executive Vice President
David W. Gryska
Corporate headquarters
Wilmington, Delaware

Forecasts

Partner Offers

Search for Jobs